梅州激光去眼袋(梅州怀孕2个月流产要多少钱) (今日更新中)

BEIJING, July 13 (Xinhuanet) -- Gasoline powers vehicles all around the world, but a sick Chinese man has been drinking the sticky liquid for 42 years under the illusion that it can relieve his physical pain.Chen Dejun, 71, lives by himself in shabby thatched cottage on a hill in Shuijiang township, Nanchuan district of southwest China's Chongqing municipality. The short and bony man said he drinks 3 to 3.5 kilograms of gasoline every month, which he buys from a station at the foot of the hill.Chen is known locally as a stonecutter and master of weaving bamboo with a good business sense. But he’s also known for his undying love of drinking gasoline.He developed the habit back in 1969 when he suddenly began coughing and felt pain in his chest. Seeing no progress after trying some medicine, he took up the folk remedy of drinking kerosene, Chongqing Evening News reported.It turned out to be helpful for him after the first sip, and he since became addicted to kerosene. Then he moved on to gasoline.Chen said it is hard to calculate exactly how much gasoline he has swallowed throughout his life, but the newspaper reported Chen has consumed an estimated 1.5 tons over the past 42 years.Chen's wife Yuan Huibi and their three sons tried many times to stop Chen's addiction to gasoline, but those efforts only made the family relations tense. Eight years ago Chen moved to the cottage to live alone.Sources from Honglou Hospital in Chongqing said Chen‘s health is fine despite having symptoms of emphysema. Chen refused to receive free check ups from the hospital.Feng Fu, an associate professor with the Second Hospital Affiliated to Chongqing Medical University, said Chen may have developed some resistance to gasoline. Otherwise, Feng said, it would be impossible for Chen to live. Feng also said gasoline may only work as anaesthetic for Chen but can’t cure his pain.

RIO DE JANEIRO, July 28 (Xinhua) -- Brazilians are eating a lot of rice and beans as well as high-calorie junk food lacking nutrition, a study released Thursday by the Brazilian Institute of Geography and Statistics (IBGE) found.According to the study, over 90 percent of Brazilians eat daily helpings of fruits and vegetables lower than the levels recommended by the Health Ministry (400 grams). Also,the consumption of sugary drinks (juices, fruit drinks and soft drinks) is twice as high as recommended by the ministry.Rice and beans, along with coffee and juices, are the most popular in Brazilians' diet. Teenagers are the main consumers of those drinks, drinking twice as much as adults. Men eat less greens and fruits than women, but drink five times more alcohol.In urban areas, the consumption of beer, soft drinks, sandwiches, and salty bread is higher. Brazilians in rural areas have a healthier diet, richer in rice, beans, fish, cassava flour, and sweet potatoes.Along with a lack of physical activity, the Brazilians' poor diet was cited as one of the main causes of obesity in the country. According to a Health Ministry study published in April, 48 percent of Brazilians are overweight, and 15 percent are obese.

SAN FRANCISCO, July 20 (Xinhua) -- Google announced on Wednesday that it has reached a deal with author J.K. Rowling to launch the series of Harry Potter ebooks on Google's platform.When the series of Harry Potter ebooks launch on Pottermore.com in early October, the bestsellers will be available in the United States via Google eBooks platform, said Google in a blog post.When customers buy a Harry Potter ebook from Pottermore.com, they will be able to choose to keep it in their Google's online library in the cloud, as well as other e-reading platforms.Google said Google eBooks can be read on most devices with a modern browser, through Google apps for iOS and Android smartphones and tablets, and on more than 80 e-readers.Meanwhile, Rowling will continue to issue announcements via YouTube, as she announced Pottermore.com in June.The two sides also agreed to make Google Checkout the preferred third-party payment platform for all purchases made on Rowling's Pottermore.com.Pottermore.com, which will be launched on July 31, will sell ebook and audiobook versions of the seven Harry Potter novels, as well as additional content including background details and settings.According to The Times, the Harry Potter brand value is estimated to be more than 15 billion U.S. dollars. The deal could make Google move some e-reader customers from competitors like Amazon, whose e-reader Kindle does not support Google eBooks.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Aug. 25 (Xinhua) -- China pledged on Thursday to make more efforts to aid people living in the drought-stricken Horn of Africa in collaboration with the International Committee for the Red Cross (ICRC)."We noticed that the ICRC launched an appeal regarding the situation in the Horn of Africa. The Red Cross Society of China (RCSC) has decided to donate 4 million yuan (about 623,000 U.S. dollars) to the ICRC for its humanitarian aid in the region," said Hua Jianmin, president of the RCSC, while meeting with visiting ICRC President Jakob Kellenberger in Beijing on Thursday.Earlier this month, the RCSC donated 8 million yuan (1.25 million dollars) to famine-plagued countries in the Horn of Africa to be used for emergency humanitarian aid.A donation of 2 million yuan was sent to Kenya through the country's Red Cross organization, while another 2 million went to Ethiopia. The other 4 million yuan was donated to other countries in the region.The Chinese government has decided to provide a total of 90 million yuan (14 million dollars) in emergency food assistance to countries in the Horn of Africa."The Red Cross Society of China is willing to work together with the International Committee for the Red Cross to meet the needs of those who have been affected (by the droughts)," Hua said.Some 12.4 million people in Kenya, Ethiopia, Somalia and other countries in the region are in dire need of food due to a serious drought, the worst to hit the region since the 1980s.

来源：资阳报